Treatment resistance

What treatment resistance means

For major depressive disorder, treatment-resistant depression is most commonly defined as failure to respond to at least two adequate trials of antidepressants from different classes, at effective doses, for adequate duration (usually at least 6 weeks each). More stringent definitions require failure of psychotherapy trials as well.

For obsessive-compulsive disorder, treatment resistance is often defined as failure to respond to at least two adequate trials of SSRIs plus exposure and response prevention therapy at adequate doses and durations.

For schizophrenia, treatment-resistant schizophrenia is usually defined by failure to respond to at least two adequate trials of antipsychotics at adequate doses and durations, and it's the clinical picture that opens the way to clozapine.

The specific numbers vary between guidelines. What's common across definitions:

• Adequate dose. The medication was given at an effective dose, not a low starter dose.
• Adequate duration. The medication was given long enough for effect to develop (6 to 12 weeks for most antidepressants, longer for some other conditions).
• Adequate documentation. There's a clear record of what was tried and how it went.
• Consideration of adherence. If medications weren't taken consistently, that's not resistance in the true sense.

Common causes of apparent resistance

Before diagnosing true treatment resistance, several things are typically considered:

• Misdiagnosis. Bipolar depression treated as unipolar depression often doesn't respond; the diagnosis needs revisiting. Adult ADHD complicating depression can look like resistance.
• Inadequate treatment. Sub-therapeutic dose, too short a duration, or partial adherence.
• Untreated co-occurring conditions. Anxiety, substance use, PTSD, or medical conditions can all keep depression from responding.
• Medical contributors. Thyroid dysfunction, sleep apnea, vitamin deficiencies, and some medications can drive persistent depression.
• Substance use, particularly alcohol and cannabis, which can maintain depression.

Working through this list before escalating treatment often reveals a solvable problem.

What comes next

For treatment-resistant depression, the evidence-based next steps include:

• Switching to a different antidepressant class
• Augmentation with an atypical antipsychotic (aripiprazole, brexpiprazole, quetiapine, olanzapine)
• Augmentation with lithium (particularly if any bipolar features)
• Augmentation with thyroid hormone
• Adding psychotherapy specifically if only medication has been tried
• Ketamine or esketamine (see the specific entry)
• Transcranial magnetic stimulation (TMS)
• Electroconvulsive therapy (ECT), particularly for severe or urgent cases

The choice depends on the picture, prior treatments, patient preference, and access.

For treatment-resistant OCD:

• Higher SSRI doses than typical, sometimes above FDA-approved ceilings under specialist care
• Switching among SSRIs
• Clomipramine (a tricyclic with strong evidence for OCD)
• Adding an atypical antipsychotic
• Intensive exposure and response prevention
• Deep brain stimulation (in specialist centers, for severe cases)

For treatment-resistant schizophrenia:

• Clozapine has the strongest evidence, and is unique in this indication. It requires blood-count monitoring but produces meaningful improvement in a substantial proportion of people who didn't respond to other antipsychotics.

What treatment resistance is not

It's not a personal failing. Treatment resistance reflects the biology of the condition, not effort or attitude.

It's not the end. The proportion of people who eventually achieve remission with an appropriate sequence of treatments is substantial, even when standard first-line options haven't worked.

It's not always permanent. What was resistant now may respond to a different combination later, and adherence to next-line treatments improves the odds substantially.